drugset / Trial / NCT00532558

Efficacy of Lapaquistat Acetate on Blood Cholesterol Levels in Treating Subjects With Hypercholesterolemia

NCT00532558

Phase 3 Terminated 657 enrolled Takeda
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of the study is to determine the reduction of LDL-cholesterol level after treatment with 50 mg per day of lapaquistat acetate once daily (QD).

Timeline

Start
2007-10
Primary completion
2008-05
Completion
2008-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Lapaquistat acetate Small molecule 50 mg Oral

Indications